A
Aelix Therapeutics
Developing novel vaccines to cure HIV infection
About Aelix Therapeutics
AELIX Therapeutics, headquartered in Barcelona, Spain, is a clinical-stage biotechnology company specializing in the development of therapeutic HIV vaccines. The company aims to integrate these vaccines into broader HIV cure and eradication strategies. Originating as a spin-off from HIVACAT, a renowned Catalan public-private consortium, AELIX leverages cutting-edge research to advance its mission. The company holds a worldwide, exclusive license for the development and commercialization of the HTI immunogen, a key component in their vaccine development. AELIX Therapeutics primarily operates in the biotechnology and pharmaceutical markets, targeting healthcare providers and research institutions focused on HIV treatment and eradication. The business model revolves around the development, clinical testing, and eventual commercialization of its proprietary vaccines. Revenue generation is expected through licensing agreements, partnerships, and direct sales of the developed vaccines.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| LATE VCEquity / VC | Sep 2021 | $2.2M | $8.7M | Undisclosed | — |
| GRANT✓Other financing | Jun 2017 | $55K | — | Undisclosed | — |
Growth signals
Latest recorded traffic for Aelix Therapeutics is 0 monthly website visits, down 100% over the last three months. Aelix Therapeutics's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Aelix Therapeutics in the Barcelona ecosystem
The Aelix Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A1 investor entered at this stage
Ysios Capital
Other known investors6 additional known investors
August Pi i Sunyer Biomedical Research Institute
ICREA
IRSICAIXA
Caixa Capital Risc
CDTI Innvierte
Criteria Venture Tech
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Aelix Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Aelix Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.










